Trial Profile
Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Axial spondyloarthritis
- Focus Therapeutic Use
- Acronyms MANGO
- 04 Jun 2022 Results examining the construct validity and responsiveness of ASAS HI (Assessment of Spondyloarthritis International Society Health Index ) in relation to TNFi treatment, presented at the 23rd Annual Congress of the European League Against Rheumatism
- 20 Apr 2020 Results published in the Rheumatology
- 04 Jan 2019 Status changed from not yet recruiting to completed.